The expression of therapy-related CD14+ monocytes in these groups was significantly different, which suggests that the activation of AP-1 family and the therapy-related CD14+ monocytes may help identify and screen heart failure patients suitable for the MSCs therapy. The gene discussed is FOS; the disease is heart failure.